Oxford Biomedica plc

Summary

A gene-therapy developer needs a reliable way to carry genetic material into cells and manufacture that delivery system consistently. Oxford Biomedica, operating as OXB, develops and produces viral vectors for biotechnology and pharmaceutical customers. It is a contract development and manufacturing business, so it earns fees from customer programmes rather than automatically owning the medicines those programmes produce. Its Oxford base forms part of an international manufacturing network serving clinical development and commercial supply.

Customer benefits

• Vector-development work helps customers turn a therapeutic design into a process that can be manufactured repeatedly.
• Specialist facilities give developers access to production capacity without building every manufacturing capability internally.
• Quality control and process support connect early development with the requirements of clinical and commercial supply.

What sets it apart

Experience with vector processes and regulated manufacturing can make OXB useful across several customer programmes. The attraction is a service platform serving multiple therapies, but diversification does not eliminate clinical risk. A customer’s funding shortage or failed trial can still reduce demand for batches and leave expensive facilities underused.

Growth plans

The September 2026 interim results focus on converting signed customer work, improving capacity use and expanding the manufacturing platform. Management maintained full-year revenue guidance of £180m–£200m at constant currency and a mid-single-digit adjusted operating EBITDA margin excluding one-off items. These are management targets, not the outcome already achieved in the first half.